- Home
- USIO vs KZR Comparison
USIO vs KZR Comparison
Compare USIO & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- KZR
- Stock Information
- Founded
- USIO 1998
- KZR 2015
- Country
- USIO United States
- KZR United States
- Employees
- USIO 111
- KZR N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- KZR Health Care
- Exchange
- USIO Nasdaq
- KZR Nasdaq
- Market Cap
- USIO 37.1M
- KZR 29.7M
- IPO Year
- USIO N/A
- KZR 2018
- Fundamental
- Price
- USIO $1.37
- KZR $6.19
- Analyst Decision
- USIO Strong Buy
- KZR Hold
- Analyst Count
- USIO 1
- KZR 4
- Target Price
- USIO $4.00
- KZR $6.00
- AVG Volume (30 Days)
- USIO 58.8K
- KZR 53.2K
- Earning Date
- USIO 11-12-2025
- KZR 11-12-2025
- Dividend Yield
- USIO N/A
- KZR N/A
- EPS Growth
- USIO N/A
- KZR N/A
- EPS
- USIO N/A
- KZR N/A
- Revenue
- USIO $83,710,461.00
- KZR N/A
- Revenue This Year
- USIO $8.71
- KZR N/A
- Revenue Next Year
- USIO $12.48
- KZR N/A
- P/E Ratio
- USIO N/A
- KZR N/A
- Revenue Growth
- USIO 1.46
- KZR N/A
- 52 Week Low
- USIO $1.24
- KZR $3.53
- 52 Week High
- USIO $2.92
- KZR $7.65
- Technical
- Relative Strength Index (RSI)
- USIO 43.39
- KZR 68.12
- Support Level
- USIO $1.36
- KZR $6.11
- Resistance Level
- USIO $1.42
- KZR $6.29
- Average True Range (ATR)
- USIO 0.05
- KZR 0.13
- MACD
- USIO -0.01
- KZR -0.07
- Stochastic Oscillator
- USIO 18.75
- KZR 65.81
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.